Andrea Jefferson Saboor
Family · Atlanta, GANPI 1407895618
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Viiv Healthcare Company at 51.0% of the total. Reporting peaked in 2022 at $4,978 and has fallen 51.3% since, to $2,423 in 2025. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $61.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$7K
- Gilead$5K
- Janssen Products, LP$653
- Merck$645
- Novo Nordisk$205
- Exact Sciences$49
- plus $288 from 10 others
What the payments were for
- Consulting fees$3,97029%
- Travel & lodging$2,51918%
- Food & beverage$7,05952%
- Education$1001%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 102 | $6,956 |
| Gilead | 67 | $4,852 |
| Janssen Products, LP | 5 | $653 |
| Merck | 21 | $645 |
| Novo Nordisk | 6 | $205 |
| Exact Sciences | 3 | $49 |
| EMD Serono, Inc. | 3 | $49 |
| Verity Pharmaceuticals Inc. | 3 | $48 |
| Theratechnologies Inc. | 2 | $34 |
| Lilly USA, LLC | 2 | $33 |
| Astellas Pharma US Inc | 1 | $27 |
| Abbott | 1 | $22 |
| Napo Pharmaceuticals Inc | 1 | $21 |
| GSK | 1 | $19 |
| Antares Pharma, Inc. | 1 | $18 |
| Johnson & Johnson | 2 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,648 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 64 | $250,162 |
| DovatoDolutegravir Sodium/Lamivudine | 33 | $91,591 |
| JulucaDolutegravir/Rilpivirine | 25 | $87,121 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $43,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya | $4,852 | $293,94976 claims |
| Viiv Healthcare CompanyDovato, Juluca | $6,956 | $178,71258 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Atlanta
- Stacey TatroeAtlanta$38K
- Brandy HughesAtlanta$29K
- Cecile MartinAtlanta$23K
- Terri CowanAtlanta$21K
- Brandi Pinckney-GreeneAtlanta$18K
- Michelle SarievAtlanta$18K
- Christopher VreelandAtlanta$17K
- Angelica MillerAtlanta$15K
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.